U.S., April 19 -- ClinicalTrials.gov registry received information related to the study (NCT06933914) titled 'Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria' on April 11.
Brief Summary: This is a multicenter, single-arm, open-label study to characterize long-term safety and tolerability of MY008211A tablets and to provide access to MY008211A tablets to patients with PNH who have completed Phase 2 or 3 studies with MY008211A tablets.
Study Start Date: Nov. 30, 2024
Study Type: INTERVENTIONAL
Condition:
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Intervention:
DRUG: MY008211A tablets
Participants will receive MY008211A at a dose of 400 mg orally b.i.d
Recruitment Status: RECR...